United Therapeutics announced on Tuesday that it received U.S. Food and Drug Administration approval for its therapeutic Tyvaso DPI.
Tyvaso DPI marks the first approval of a dry powder inhaler for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
{iframe}https://www.biospace.com/article/united-therapeutics-moving-ahead-with-inhaled-hypertension-therapeutic/{/iframe}